Terns Pharmaceuticals stock extends gain after positive CML drug data By Investing.com
Update: 2025-11-04
Description
Terns Pharmaceuticals' stock surged by 120% in two days following positive trial results for its experimental treatment, TERN-701, which showed a major molecular response in 64% of patients with relapsed or hard-to-treat chronic myeloid leukemia. Wall Street analysts, such as Truist Securities and H.C. Wainwright, raised their price targets and sales expectations, while BMO Capital increased the probability of success to 70% and estimated potential sales in the billions. With no dose-limiting toxicities and mostly mild side effects, Terns Pharmaceuticals is now under the spotlight as patients and doctors await further developments.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
